What the company does
Alteogen is a South Korean biotechnology company that develops drug technologies and biologic medicines.
It is best known for a platform that converts medicines given by intravenous infusion into versions that can be given as a quick under-the-skin injection, which it licenses to global drugmakers. The company also develops biosimilars and its own novel treatments. It earns money largely through licensing deals and related milestone payments.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$156.4M
▲ +109.9% YoY
Operating profit · FY2025
US$77.5M
▲ +320.8% YoY
Net income · FY2025
US$105.2M
▲ +139.2% YoY
Revenue
- FY2023US$69.9M
- FY2024US$74.5M
- FY2025US$156.4M
Operating profit
- FY2023−US$7.1M
- FY2024US$18.4M
- FY2025US$77.5M
Net income
- FY2023−US$2.6M
- FY2024US$44M
- FY2025US$105.2M
Key ratios (FY2025)
ROE
31.9%
Debt/Eq
53.8%
Op. margin
49.5%
Net margin
67.3%
Rev. YoY
▲ +109.9%
Why it matters · Context, not a recommendation
Much of its value rests on licensing its injection-technology platform to large pharmaceutical companies.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?